Xipere, the first FDA-approved therapy for suprachoroidal use for the treatment of macular edema associated with uveitis, has been launched in the United States, according to a press release from Bausch + Lomb and Clearside Biomedical.
Xipere (triamcinolone acetonide injectable suspension) was approved in October 2021 based on the results of the phase 3 PEACHTREE trial. Among patients treated with Xipere, 47% achieved an improvement in best corrected visual acuity of at least 15 letters from baseline at 24 weeks compared with 16% of patients in the control arm (P < .01).
(Read more...)